Authors: Hakamies-Blomqvist, L Luoma, ML Sjostrom, J Pluzanska, A Sjodin, M Mouridsen, H Ostenstad, B Mjaaland, I Ottosson, S Bergh, J Malmstrom, PO Blomqvist, C

Citation: L. Hakamies-blomqvist et al., Timing of quality of life (QoL) assessments as a source of error in oncological trials, J ADV NURS, 35(5), 2001, pp. 709-716

Authors: Sjostrom, J Blomqvist, C Heikkila, P von Boguslawski, K Raisanen-Sokolowski, A Bengtsson, NO Mjaaland, I Malmstrom, P Ostenstadt, B Bergh, J Wist, E Valvere, V Saksela, E

Citation: J. Sjostrom et al., Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer, CLIN CANC R, 6(8), 2000, pp. 3103-3110

Authors: Hakamies-Blomqvist, L Luoma, ML Sjostrom, J Pluzanska, A Sjodin, M Mouridsen, H Ostenstad, B Mjaaland, I Ottosson-Lonn, S Bergh, J Malmstrom, PO Blomqvist, C

Citation: L. Hakamies-blomqvist et al., Quality of life in patients with metastatic breast cancer receiving eitherdocetaxel or sequential methotrexate and 5-fluorouracil. A multicentre randomised phase III trial by the Scandinavian Breast Group, EUR J CANC, 36(11), 2000, pp. 1411-1417

Authors: Sjostrom, J Blomqvist, C Mouridsen, H Pluzanska, A Ottosson-Lonn, S Bengtsson, NO Ostenstad, B Mjaaland, I Palm-Sjovall, M Wist, E Valvere, V Anderson, H Bergh, J

Citation: J. Sjostrom et al., Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group, EUR J CANC, 35(8), 1999, pp. 1194-1201